All News

In 2016, our "Hands On" section included articles about bulbomembranous urethroplasty, recurrent urinary tract infections, transgender surgery, and more.

Results of a study analyzing global trends in mortality attributable to urolithiasis show that the rate declined over a recent 20-year period.

Researchers have found that the anxiety men often experience after being diagnosed with prostate cancer could lead to potentially unnecessary treatment options.

Researchers evaluate an experimental treatment called vascular-targeted photodynamic therapy in men with localized prostate cancer.

Getting your finances in order can be overwhelming; here are a few good places to start. Plus, find out if it’s too late to make an IRA contribution.

Results of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.

Findings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.

In the wake of heated criticism about lengthy wait times for veterans’ care at Veterans Health Administration hospitals, the U.S. Department of Veterans Affairs has moved to allow advanced-practice registered nurses to practice to their full authority without physician oversight and regardless of individual state law in VA facilities.

In this month's Letters to the Editor, one reader responds to an article on testosterone therapy in women and another looks to address urology's work force shortage.

In this edition of Men’s Health Mythbuster, Matthew Pollard, MD, Jesse N. Mills, MD look at what impact stress really has on the cardiovascular system.

Whether or not medical expulsive therapy (MET) is a sound recommendation for patients with kidney or ureteral stones is a matter of debate.

Our #LetsTalkMensHealth section offers clinical tips on the care of male patients. In 2016, articles in this section tackled a variety of subjects, including the Affordable Care Act, epigenetics and genetics, and BPH and prostate cancer prevention.

Dr. Henry Rosevear apologizes to those he may have hurt with his prescription habits for pain control and discusses the steps he is taking to help remedy the narcotics epidemic.

Administering sipuleucel-T (Provenge) before rather than after androgen deprivation therapy in men with biochemically recurrent prostate cancer appears to result in a more robust immunologic response, according to a recent study.

Statement authors recommend using immunotherapy prior to an androgen receptor-targeted agent in men with metastatic castration-resistant prostate cancer.

Urology resident, Nirmish Singla, MD, goes over some of the ways urologists can stay educated and informed in the infinite and dynamic curriculum that defines the medical field.

The practice of performing concurrent and overlapping surgeries in hospitals and ambulatory surgery centers across the nation has come under scrutiny by the Senate Finance Committee, and hospitals and surgeons are on notice that some practices that may have been commonplace in the past need to change.

Robert A. Dowling, MD, summarizes key findings from the recent CMS report “National Health Spending: Faster Growth In 2015 As Coverage Expands and Utilization Increases."

In this interview, Sarah E. McAchran, MD, discusses the need for urology-gynecology collaboration, the background behind the ABMS recognizing the female pelvic medicine and reconstructive surgery subspecialty, and how barriers to full integration of providers treating pelvic floor disorders can be overcome.

"Those patients (and their caregivers) who take ownership of more aspects of their health care experience, including relevant and personalized information, will have better outcomes," writes Steven A. Kaplan, MD.

With the New Year being associated with resolutions of improved health and fitness and reducing the number on the scale, it seems a particularly appropriate time to share some information about how obesity impacts urologic care and treatment, and the impact of obesity on malpractice litigation.

Sanofi Pasteur recently announced that it is discontinuing its BCG products TheraCys and ImmuCyst, prompting fears of a shortage of BCG for bladder cancer patients. In this interview, Dr. Benjamin J. Davies, associate professor of urology at the University of Pittsburgh School of Medicine, discusses the implications of the announcement and what’s next for patients and clinicians.